Tvardi Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +53.1% | -94.5% | +204.7% | -25.9% | -50.5% | |
| – | – | – | +27.6% | +1.6% | +338.6% | |
| – | – | -49.3% | +281.4% | -248.6% | – | |
| – | -88.8% | +28.2% | +4,650.0% | -56.0% | -100.0% | |
| – | -76.6% | +363.1% | – | +12.1% | -120.7% | |
| – | – | – | – | – | -100.0% | |
| – | +19.1% | -100.0% | +953,675.0% | -109.4% | – | |
| – | -236.3% | – | – | – | – | |
| – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.